Servier Breaks Up With Pharmacyclics, Leaving Future Uncertain
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmacyclics and Servier decided to just be friends, leaving the biotech on the hook for the development of the mid-stage HDAC inhibitor abexinostat.